Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigenin prostate cancer cell lines: Implications for PSA surrogacy
Academic Article
Overview
MeSH Major
Antigens, Surface
Antineoplastic Agents
Glutamate Carboxypeptidase II
Prostate-Specific Antigen
Prostatic Neoplasms
Receptors, Androgen
Taxoids
abstract
While DOC did not affect PSMA expression, it was unexpectedly found to down-regulate AR and PSA. DOC-induced down-regulation of AR might be one of the anti-tumor mechanisms active in PC. Down-regulation of PSA may account for the significantly higher PSA response rates (45-50%) relative to measurable response rates (8-17%) reported in DOC PC trials and have implications for PSA surrogacy observations derived from DOC trials.
